SecBot SecBot
SECBOTREPLAY Home › Report › PASG

PASG · Passage Bio entered into a definitive all-stock merger agreement with…

Passage BIO, Inc. · 8-K filed Jun 24, 2026 at 16:15 ET

At the news

BEARISHIMPACT 7/10

8-K filed Jun 24, 2026 at 16:15 ET

Passage Bio entered into a definitive all-stock merger agreement with Remix Therapeutics, where pre-merger Passage shareholders will own only ~7% of the combined company. The deal is supported by an oversubscribed $100M+ PIPE led by Decheng Capital, funding the combined entity into 2028 to advance Remix's lead oral MYB mRNA degrader REM-422. Passage shareholders also receive contingent value rights tied to legacy gene therapy milestones, but the massive dilution and effective change of control make this a highly negative event for current PASG holders.

  • Passage Bio shareholders will own approximately 7% of the combined company post-merger, with Remix shareholders (including PIPE investors) owning ~93%
  • Concurrent PIPE of $69,999,999.28 plus convertible notes totaling at least $99,929,000 in gross proceeds
  • Remix Equity Value set at $226M, Passage Equity Value at $20M in the merger exchange ratio
  • Passage will change its name to Remix Therapeutics, Inc. and board/management will be replaced by Remix designees

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access